Several other equities analysts have also recently issued reports on the company. SunTrust Banks upped their price objective on Accenture to $180.00 and gave the company a “hold” rating in a research report on Friday, March 29th. They noted that the move was a valuation call. Oppenheimer lowered their price objective on Littelfuse from $215.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. Royal Bank of Canada reaffirmed an “outperform” rating on shares of in a research report on Tuesday, June 25th. Zacks Investment Research raised DLH from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, CIBC lowered their price objective on Rocky Mountain Dealerships from C$10.50 to C$10.00 in a research report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $22.17.
ATNX stock opened at $19.98 on Thursday. Athenex has a 12-month low of $9.38 and a 12-month high of $21.11. The company has a current ratio of 2.22, a quick ratio of 1.85 and a debt-to-equity ratio of 0.57. The company has a 50 day simple moving average of $17.25.
Athenex (NASDAQ:ATNX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.08). The business had revenue of $25.31 million during the quarter, compared to the consensus estimate of $19.55 million. Athenex had a negative net margin of 189.86% and a negative return on equity of 96.55%. As a group, analysts forecast that Athenex will post -1.73 EPS for the current year.
In other news, Director Stephanie A. Davis purchased 10,000 shares of the stock in a transaction dated Wednesday, June 26th. The shares were purchased at an average cost of $18.00 per share, with a total value of $180,000.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $180,000. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jordan Kanfer purchased 2,500 shares of the stock in a transaction dated Thursday, June 6th. The shares were purchased at an average cost of $15.01 per share, for a total transaction of $37,525.00. Following the completion of the acquisition, the director now directly owns 4,184 shares in the company, valued at $62,801.84. The disclosure for this purchase can be found here. Insiders have bought a total of 318,210 shares of company stock worth $5,111,581 over the last three months. Insiders own 18.80% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its holdings in shares of Athenex by 913,400.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,135 shares of the company’s stock valued at $112,000 after buying an additional 9,134 shares during the period. Prudential Financial Inc. purchased a new stake in shares of Athenex in the 4th quarter worth $147,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Athenex in the 1st quarter worth $158,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Athenex by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,245 shares of the company’s stock worth $181,000 after purchasing an additional 11,125 shares in the last quarter. Finally, Private Advisor Group LLC increased its stake in shares of Athenex by 6.2% in the 4th quarter. Private Advisor Group LLC now owns 17,091 shares of the company’s stock worth $217,000 after purchasing an additional 991 shares in the last quarter. 31.21% of the stock is currently owned by hedge funds and other institutional investors.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Featured Article: What is Put Option Volume?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.